Applied TherapeuticsAPLT
APLT
About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Employees: 37
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
220% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 15
92% more capital invested
Capital invested by funds: $501M [Q2] → $961M (+$460M) [Q3]
34% more funds holding
Funds holding: 93 [Q2] → 125 (+32) [Q3]
4.18% more ownership
Funds ownership: 94.0% [Q2] → 98.19% (+4.18%) [Q3]
3% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
2% less call options, than puts
Call options by funds: $17.1M | Put options by funds: $17.5M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
129%
upside
Avg. target
$4.13
530%
upside
High target
$8
1,121%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
RBC Capital Brian Abrahams 10% 1-year accuracy 8 / 79 met price target | 129%upside $1.50 | Sector Perform Maintained | 20 Dec 2024 |
UBS Esther Rajavelu 33% 1-year accuracy 1 / 3 met price target | 205%upside $2 | Neutral Downgraded | 2 Dec 2024 |
Citigroup Yigal Nochomovitz 27% 1-year accuracy 12 / 45 met price target | 1,121%upside $8 | Buy Maintained | 29 Nov 2024 |
Baird Brian Skorney 21% 1-year accuracy 5 / 24 met price target | 663%upside $5 | Outperform Maintained | 29 Nov 2024 |
Financial journalist opinion
Based on 388 articles about APLT published over the past 30 days
Neutral
Accesswire
4 hours ago
Applied Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=124264&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
4 hours ago
APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"), of the important February 18, 2025 lead plaintiff deadline. So what: If you purchased Applied Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
4 hours ago
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=124260&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
4 hours ago
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT
NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Applied Therapeutics, Inc. (NASDAQ: APLT) between January 3, 2024 and December 2, 2024, both dates inclusive (the “Class Period”), of the important February 18, 2025 lead plaintiff deadline.
Neutral
Accesswire
5 hours ago
Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT
NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=124242&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
5 hours ago
APLT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, inclusive (the “Class Period”), have until Tuesday, February 18, 2025 to seek appointment as lead plaintiff of the Applied Therapeutics class action lawsuit. Captioned Alexandru v. Applied Therapeutics, Inc., No. 24-cv-09715 (S.D.N.Y.), the Applied Therapeutics class action lawsuit charges Applied Therapeutics as well as certain of Applied Therapeutics' top executives with violations of the Securities Exchange Act of 1934.
Neutral
Accesswire
6 hours ago
Contact Levi & Korsinsky by February 18, 2025 Deadline to Join Class Action Against Applied Therapeutics, Inc.(APLT)
NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=124231&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
7 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - APLT
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Neutral
Accesswire
7 hours ago
February 18, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against APLT
NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=124211&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
8 hours ago
February 18, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against APLT
NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=124173&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™